Article
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.
Antimicrobial agents and chemotherapy - 1 Feb 2013
Kothary Vishesh, Scherl Ellen J, Bosworth Brian, Jiang Zhi-Dong, Dupont Herbert L, Harel Josee, Simpson Kenneth W, Dogan Belgin
Abstract excerpt
Escherichia coli is implicated in the pathogenesis of inflammatory bowel disease (IBD). Rifaximin, a nonabsorbable derivative of rifampin effective against E. coli, improves symptoms in mild-to-moderate IBD. However, rifaximin resistance can develop in a single step in vitro. We examined the prev...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.